How to buy Sangamo Therapeutics stock (SGMO)

Sangamo Therapeutics is a biotechnology business based in the US. Sangamo Therapeutics shares (SGMO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.35 – an increase of 21.13% over the previous week. Sangamo Therapeutics employs 405 staff and has a trailing 12-month revenue of around $12.3 million.

Our top picks for where to buy Sangamo Therapeutics stock

Buy Sangamo Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sangamo Therapeutics stock price (NASDAQ: SGMO)

Use our graph to track the performance of SGMO stocks over time.

Sangamo Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-08.

Latest market close	$2.35
52-week range	$0.30 - $3.18
50-day moving average more info button	$1.27
200-day moving average more info button	$0.82
Wall St. target price	$4.80
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.24

Is it a good time to buy Sangamo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sangamo Therapeutics price performance over time

Historical closes compared with the close of $2.82 from 2024-12-17

1 week (2024-12-12)	47.64%
1 month (2024-11-19)	43.88%
3 months (2024-09-19)	213.33%
6 months (2024-06-18)	569.52%

1 year (2023-12-19)	611.40%
2 years (2022-12-19)	-8.74%
3 years (2021-12-17)	8.17
5 years (2019-12-19)	8.66

Sangamo Therapeutics financials

Revenue TTM	$12.3 million
Gross profit TTM	$-138,599,000
Return on assets TTM	-58.29%
Return on equity TTM	-194.05%
Profit margin	0%
Book value	$0.47
Market Capitalization more info button	$563.2 million

TTM: trailing 12 months

Sangamo Therapeutics share dividends

We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months.

Sangamo Therapeutics share price volatility

Over the last 12 months, Sangamo Therapeutics's shares have ranged in value from as little as $0.304 up to $3.179. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 1.098. This would suggest that Sangamo Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Sangamo Therapeutics overview

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc. ; Kite Pharma, Inc.

Frequently asked questions

What percentage of Sangamo Therapeutics is owned by insiders or institutions?
Currently 2.381% of Sangamo Therapeutics shares are held by insiders and 38.536% by institutions. How many people work for Sangamo Therapeutics?
Latest data suggests 405 work at Sangamo Therapeutics. When does the fiscal year end for Sangamo Therapeutics?
Sangamo Therapeutics's fiscal year ends in December. Where is Sangamo Therapeutics based?
Sangamo Therapeutics's address is: 501 Canal Blvd, Richmond, CA, United States, 94804 What is Sangamo Therapeutics's ISIN number?
Sangamo Therapeutics's international securities identification number is: US8006771062 What is Sangamo Therapeutics's CUSIP number?
Sangamo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 800677106